(223)RaCl2
A radium molecular entity with formula 223RaCl2. Used as as a radiotherapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. An alpha-emitter, radium-223 has a half-life of 11.4 days. — ChEBI
Safety documents & references
Supplier matching mattersFind the safety document for your specific supplier, product number and grade.
Find a product-specific SDS
Safety guides and government classification records are not a manufacturer’s SDS. Match supplier, product number, concentration, physical form, region and revision before using a document.
Identity & molecular properties
Source-linked values| CAS number | 444811-40-9 | ChEBI ↗ |
| Molecular formula | Cl2 | ChEBI ↗ |
| Molar mass | 293.925 g/mol | ChEBI ↗ |
| Monoisotopic mass | 292.95621 Da | ChEBI ↗ |
| Formal charge | 0 | ChEBI ↗ |
| ChEBI identifier | CHEBI:74895 | ChEBI ↗ |
Names & structural identifiers
Copy any identifier(223)RaCl2((223)Ra)radium dichlorideRWRDJVNMSZYMDV-SIUYXFDKSA-L[Cl][223Ra][Cl]InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3Names & synonyms
Names are supplied by ChEBI. Trade names and related synonyms may describe a broader product context.
Classification & relationships
ChEBI ontologyRoles recorded in ChEBI
Database role annotations describe reported biological or chemical roles; they are not product approvals or recommendations for use.
Mass ↔ amount of substance
Calculated from sourced massUses 293.925 g/mol from ChEBI. Assumes the substance described by this record; no purity or concentration correction is applied.
Research & patent references
Selected source associationsSources & record history
Checked 27 Sep 2026Release 255, 9 September 2026. ChEBI three-star (manually annotated) source entry. View original record ↗ · CC BY 4.0
PubCAS formats source data, connects references and computes explicitly labelled conversions. CAS cross-references are supplied by ChEBI; they do not constitute CAS verification or endorsement.